Corvus Pharmaceuticals, Inc. Just Filed Its Quarterly Report: 3. Net Loss per S...



3. Net Loss per Share



 



The following table shows the calculation of net loss per share (in thousands, except share and per share data):



 

































































































































































 




 




 




 




 




 




 




 




 




 




 




 




 




 




 




 




Three Months Ended




 




Six Months Ended




 




 




 




June 30, 




 




June 30, 




 




 




    




2019




    




2018




    




2019




    




2018




    




Numerator:




 




 




  




 




 




  




 




 




  




 




 




  




 




Net loss - basic and diluted




 




$




(12,978)




 




$




(11,631)




 




$




(24,621)




 




$




(25,932)




 




Denominator:




 




 




 




 




 




  




 




 




 




 




 




  




 




Weighted average common shares outstanding




 




 




29,329,229




 




 




29,194,462




 




 




29,328,075




 




 




26,048,630




 




Less: weighted average common shares subject to repurchase




 




 




(20,079)




 




 




(214,948)




 




 




(26,570)




 




 




(263,087)




 




Weighted average common shares outstanding used to compute basic and diluted net loss per share




 




 




29,309,150




 




 




28,979,514




 




 




29,301,505




 




 




25,785,543




 




Net loss per share, basic and diluted




 




$




(0.44)




 




$




(0.40)




 




$




(0.84)




 




$




(1.01)




 




 



The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti‑dilutive effect:



 

















































































 




 




 




 




 




 




 




 




 




 




 




 




Three Months Ended




 




Six Months Ended




 




 




 




June 30, 




 




June 30, 




 




 




    




2019




    




2018




    




2019




    




2018




    




Common stock subject to repurchase




 




12,384




 




172,955




 




12,384




 




172,955




 




Outstanding options




 




4,157,154




 




3,019,438




 




4,157,154




 




3,019,438




 




Total shares of common stock equivalents




 




4,169,538




 




3,192,393




 




4,169,538




 




3,192,393




 




 

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Corvus Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020

Auto Refresh